A Phase II, Randomized, Parallel Group Safety, Efficacy, and Pharmacokinetics Study of BI 10773 (1 mg, 5 mg, 10 mg, 25 mg, and 50 mg) Administered Orally Once Daily Over 12 Weeks Compared Double Blind to Placebo With an Additional Open-label Sitagliptin Arm in Type 2 Diabetic Patients With Insufficient Glycemic Control Despite Metformin Therapy

CompletadoFase 2ClinicalTrials.gov

ID: NCT00749190Tipo: INTERVENTIONALInicio: 1 de ago de 2008

Traducción no disponible, mostrando original

Resumen

The objective of the current study is to investigate the efficacy, safety and pharmacokinetics of five doses of BI 10773 compared to placebo given for 12 weeks as add-on therapy to on going metformin therapy in patients with T2DM with insufficient glycemic control. In addition, there will be an open-label treatment arm with sitagliptin (JanuviaTM) as add-on therapy to metformin.

Elegibilidad

Edad mínima: 18 YearsEdad máxima: 79 YearsSexo: ALL

Criterios de inclusión

Male and female patients with a diagnosis of type 2 diabetes mellitus and previously treated with metformin alone or with metformin and one other oral antidiabetic drug
Stable metformin therapy of at least 1500 mg/day, or less if that is a maximum tolerated dose.
HbA1c at screening 6.5% to 9.0% for patients on metformin and one other antidiabetic drug, and HbA1c \>7.0% to 10% for patients on metformin only
HbA1c \>7.0% to 10.0% at Visit 2 (Start of Run-in)
Age \>=18 and \<80years
Body Mass Index (BMI) \<=40 kg/m2
Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and local legislation

Criterios de exclusión

Treatment with an investigational drug within 2 months prior to informed consent
Women of child-bearing potential who are nursing or pregnant, or who are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to periodic pregnancy testing during participation in the trial
Myocardial infarction, stroke or transient ischemic attack (TIA) within 6 months prior to informed consent
Impaired hepatic function
Renal insufficiency or impaired renal function
Diseases of the central nervous system or psychiatric disorders or clinically relevant neurological disorders that may interfere with participation in the trial
Chronic or clinically relevant acute infections
Current or chronic urogenital tract infection
History of clinically relevant allergy/hypersensitivity
Treatment with glitazones (e.g., rosiglitazone, pioglitazone), glucagon-like peptide (GLP-1) analogues, or insulin within 3 months prior to informed consent
Treatment with anti-obesity drugs within 3 months prior to informed consent
Treatment with systemic steroids or change in dosage of thyroid hormones within 6 weeks prior to informed consent
Alcohol abuse or drug abuse

Intervenciones

drug

BI 10773

drug

placebo

drug

sitagliptin

Ubicaciones

1245.10.54002 Boehringer Ingelheim Investigational Site

Capital Federal, Argentina

1245.10.54004 Boehringer Ingelheim Investigational Site

Capital Federal, Argentina

1245.10.54008 Boehringer Ingelheim Investigational Site

Capital Federal, Argentina

1245.10.54006 Boehringer Ingelheim Investigational Site

Mar del Plata, Argentina

1245.10.54005 Boehringer Ingelheim Investigational Site

Mendoza, Argentina

Patrocinadores

PrincipalBoehringer Ingelheim

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Phase II, Randomized, Parallel Group Safety, Efficacy, ... | EligiMed